The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization
Open accessAbstract
LRRK2 (leucine-rich repeat protein kinase 2) is mutated in a significant number of Parkinson's disease patients. Since a common mutation that replaces Gly2019 with a serine residue enhances kinase catalytic activity, small-molecule LRRK2 inhibitors might have utility in treating Parkinson's disease. However, the effectiveness of inhibitors is difficult to assess, as no physiological substrates or downstream effectors have been identified that could be exploited to develop a robust cell-based assay. We recently established that LRRK2 bound 14-3-3 protein isoforms via its phosphorylation of Ser910 and Ser935. In the present study we show that treatment of Swiss 3T3 cells or lymphoblastoid cells derived from control or a Parkinson's disease patient harbouring a homozygous LRRK2(G2019S) mutation with two structurally unrelated inhibitors of LRRK2 (H-1152 or sunitinib) induced dephosphorylation of endogenous LRRK2 at Ser910 and Ser935, thereby disrupting 14-3-3 interaction. Our results suggest that H-1152 and sunitinib induce dephosphorylation of Ser910 and Ser935 by inhibiting LRRK2 kinase activity, as these compounds failed to induce significant dephosphorylation of a drug-resistant LRRK2(A2016T) mutant. Moreover, consistent with the finding that non-14-3-3-binding mutants of LRRK2 accumulated within discrete cytoplasmic pools resembling inclusion bodies, we observed that H-1152 causes LRRK2 to accumulate within inclusion bodies. These findings indicate that dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and/or monitoring LRRK2 cytoplasmic localization can be used as an assay to assess the relative activity of LRRK2 inhibitors in vivo. These results will aid the elaboration and evaluation of LRRK2 inhibitors. They will also stimulate further research to understand how phosphorylation of Ser910 and Ser935 is controlled by LRRK2, and establish any relationship to development of Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Watterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251194298 · Cited by 2,558
The selectivity of protein kinase inhibitors: a further update
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., Mclauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,520
Self-citationCloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease
Paisán-Ruı́z, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., de Munain, A. L., Aparicio, S., Gil, A. M., Khan, N., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.10.023 · Cited by 2,405
(1995) · FEBS Letters · doi:10.1016/0014-5793(95)00357-f · Cited by 2,086
Identification of RIP1 kinase as a specific cellular target of necrostatins
Degterev, A., Hitomi, J., Germscheid, M., Ch'en, I. L., Korkina, O., Teng, X., Abbott, D., Cuny, G. D., Yuan, C., Wagner, G., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.83 · Cited by 2,059
Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor
Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., & Connelly, P. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.695 · Cited by 1,939
Healy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C. P., Goldwurm, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70117-0 · Cited by 1,425
Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403069 · Cited by 1,123
Harrington, E. A., Bebbington, D., Moore, J., Rasmussen, R. K., Ajose-Adeogun, A. O., Nakayama, T., Graham, J. A., Demur, C., Hercend, T., Diu-Hercend, A., et al. (2004) · Nature Medicine · doi:10.1038/nm1003 · Cited by 965
Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., Leeder, J. S., Freedman, M., Cohen, A., Gazit, A., et al. (1996) · Nature · doi:10.1038/379645a0 · Cited by 897
Rottlerin, a Novel Protein Kinase Inhibitor
Gschwendt, M., Muller, H. J., Kielbassa, K., Zang, R., Kittstein, W., Rincke, G., & Marks, F. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1199 · Cited by 841
BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo
Steegmaier, M., Hoffmann, M., Baum, A., Lénárt, P., Petronczki, M., Krššák, M., Gürtler, U., Garin-Chesa, P., Lieb, S., Quant, J., et al. (2007) · Current Biology · doi:10.1016/j.cub.2006.12.037 · Cited by 834
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
Pargellis, C., Tong, L., Churchill, L., Cirillo, P. F., Gilmore, T., Graham, A. G., Grob, P. M., Hickey, E. R., Moss, N., Pav, S., et al. (2002) · Nature Structural Biology · doi:10.1038/nsb770 · Cited by 833
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin
Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M. P., Beilina, A., Blackinton, J., Thomas, K. J., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.04.001 · Cited by 671
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Fan, Q.-W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M., & Weiss, W. A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.029 · Cited by 585
SU6656, a Selective Src Family Kinase Inhibitor, Used To Probe Growth Factor Signaling
Blake, R. A., Broome, M. A., Liu, X., Wu, J., Gishizky, M., Sun, L., & Courtneidge, S. A. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.23.9018-9027.2000 · Cited by 584
Burke, J. R., Pattoli, M. A., Gregor, K. R., Brassil, P. J., MacMaster, J. F., McIntyre, K. W., Yang, X., Iotzova, V. S., Clarke, W., Strnad, J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209677200 · Cited by 550
Ring, D. B., Johnson, K. W., Henriksen, E. J., Nuss, J. M., Goff, D., Kinnick, T. R., Ma, S. T., Reeder, J. W., Samuels, I., Slabiak, T., et al. (2003) · Diabetes · doi:10.2337/diabetes.52.3.588 · Cited by 532
Jaleel, M., Nichols, R. J., Deak, M., Campbell, D. G., Gillardon, F., Knebel, A., & Alessi, D. R. (2007) · Biochemical Journal · doi:10.1042/bj20070209 · Cited by 472
Self-citationKu-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
García-Martínez, J. M., Moran, J., Clarke, R. G., Gray, A., Cosulich, S. C., Chresta, C. M., & Alessi, D. R. (2009) · Biochemical Journal · doi:10.1042/bj20090489 · Cited by 455
Self-citationAlegre-Abarrategui, J., Christian, H., Lufino, M. M. P., Mutihac, R., Venda, L. L., Ansorge, O., & Wade-Martins, R. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp346 · Cited by 432
Characterization of Rictor Phosphorylation Sites Reveals Direct Regulation of mTOR Complex 2 by S6K1
Dibble, C. C., Asara, J. M., & Manning, B. D. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00735-09 · Cited by 423
Nichols, R. J., Dzamko, N., Morrice, N. A., Campbell, D. G., Deak, M., Ordureau, A., Macartney, T., Tong, Y., Shen, J., Prescott, A. R., et al. (2010) · Biochemical Journal · doi:10.1042/bj20100483 · Cited by 386
Self-citationBI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo
Sapkota, G. P., Cummings, L., Newell, F. S., Armstrong, C., Bain, J., Frodin, M., Grauert, M., Hoffmann, M., Schnapp, G., Steegmaier, M., et al. (2007) · Biochemical Journal · doi:10.1042/bj20061088 · Cited by 308
Self-citationThe discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901
Barrett, S. D., Bridges, A. J., Dudley, D. T., Saltiel, A. R., Fergus, J. H., Flamme, C. M., Delaney, A. M., Kaufman, M., LePage, S., Leopold, W. R., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.054 · Cited by 289
Phosphorylation‐dependent interactions between enzymes of plant metabolism and 14‐3‐3 proteins
Moorhead, G., Douglas, P., Cotelle, V., Harthill, J., Morrice, N., Meek, S., Deiting, U., Stitt, M., Scarabel, M., Aitken, A., et al. (1999) · The Plant Journal · doi:10.1046/j.1365-313x.1999.00417.x · Cited by 281
Leucine-Rich Repeat Kinase 2 Mutations and Parkinson's Disease: Three Questions
Greggio, E., & Cookson, M. R. (2009) · ASN Neuro · doi:10.1042/an20090007 · Cited by 272
Raynaud, F. I., Eccles, S. A., Patel, S., Alix, S., Box, G., Chuckowree, I., Folkes, A., Gowan, S., De Haven Brandon, A., Di Stefano, F., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1200 · Cited by 271
Reed, S. E., Staley, E. M., Mayginnes, J. P., Pintel, D. J., & Tullis, G. E. (2006) · Journal of Virological Methods · doi:10.1016/j.jviromet.2006.07.024 · Cited by 251
Novel IKK inhibitors: β-carbolines
Castro, A. C., Dang, L. C., Soucy, F., Grenier, L., Mazdiyasni, H., Hottelet, M., Parent, L., Pien, C., Palombella, V., & Adams, J. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00408-6 · Cited by 242
Novel Small Molecule Inhibitors of 3-Phosphoinositide-dependent Kinase-1
Feldman, R. I., Wu, J. M., Polokoff, M. A., Kochanny, M. J., Dinter, H., Zhu, D., Biroc, S. L., Alicke, B., Bryant, J., Yuan, S., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501367200 · Cited by 228
Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease
Nichols, R. J., Dzamko, N., Hutti, J. E., Cantley, L. C., Deak, M., Moran, J., Bamborough, P., Reith, A. D., & Alessi, D. R. (2009) · Biochemical Journal · doi:10.1042/bj20091035 · Cited by 197
Self-citationLRRK2 Gly2019Ser penetrance in Arab–Berber patients from Tunisia: a case-control genetic study
Hulihan, M. M., Ishihara-Paul, L., Kachergus, J., Warren, L., Amouri, R., Elango, R., Prinjha, R. K., Upmanyu, R., Kefi, M., Zouari, M., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70116-9 · Cited by 190
Self-citationCharacterization of a potent and selective small-molecule inhibitor of the PIM1 kinase
Holder, S., Zemskova, M., Zhang, C., Tabrizizad, M., Bremer, R., Neidigh, J. W., & Lilly, M. B. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0397 · Cited by 186
Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine
Song, Y., Kesuma, D., Wang, J., Deng, Y., Duan, J., Wang, J. H., & Qi, R. Z. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.03.019 · Cited by 180
Hardcastle, I. R., Cockcroft, X., Curtin, N. J., El-Murr, M. D., Leahy, J. J. J., Stockley, M., Golding, B. T., Rigoreau, L., Richardson, C., Smith, G. C. M., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050444b · Cited by 171
EGF induced SOS phosphorylation in PC12 cells involves P90 RSK-2
Douville, E., & Downward, J. (1997) · Oncogene · doi:10.1038/sj.onc.1201214 · Cited by 165
The Parkinson’s disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites
Greggio, E., Taymans, J., Zhen, Y., Ryder, J. W., Vancraenenbroeck, R., Beilina, A. G., Sun, P., Deng, J., Jaffe, H., Baekelandt, V., et al. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.08.163 · Cited by 159
Development of Dihydropyridone Indazole Amides as Selective Rho-Kinase Inhibitors
Goodman, K. B., Cui, H., Dowdell, S. E., Gaitanopoulos, D. E., Ivy, R. L., Sehon, C. A., Stavenger, R. A., Wang, G. Z., Viet, A. Q., Xu, W., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0609014 · Cited by 159
Gloeckner, C. J., Boldt, K., von Zweydorf, F., Helm, S., Wiesent, L., Sarioglu, H., & Ueffing, M. (2010) · Journal of Proteome Research · doi:10.1021/pr9008578 · Cited by 139
Solid Tumor Proteome and Phosphoproteome Analysis by High Resolution Mass Spectrometry
Zanivan, S. R., Gnad, F., Wickström, S. A., Geiger, T., Maček, B., Cox, J., Fässler, R., & Mann, M. (2008) · Journal of Proteome Research · doi:10.1021/pr800599n · Cited by 132
Gaillard, P., Jeanclaude-Etter, I., Ardissone, V., Arkinstall, S., Cambet, Y., Camps, M., Chabert, C., Church, D. J., Cirillo, R., Gretener, D., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0310986 · Cited by 129
Characterization of a Protein Kinase B Inhibitor In Vitro and in Insulin-Treated Liver Cells
Logie, L., Ruiz‐Alcaraz, A. J., Keane, M. P., Woods, Y. L., Bain, J., Márquez, R., Alessi, D. R., & Sutherland, C. D. (2007) · Diabetes · doi:10.2337/db07-0343 · Cited by 120
Self-citationInvestigation of leucine‐rich repeat kinase 2
Anand, V. S., Reichling, L. J., Lipinski, K., Stochaj, W. R., Duan, W., Kelleher, K. S., Pungaliya, P., Brown, E. L., Reinhart, P. H., Somberg, R. L., et al. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06789.x · Cited by 115
Identification of the Autophosphorylation Sites of LRRK2
Kamikawaji, S., Ito, G., & Iwatsubo, T. (2009) · Biochemistry · doi:10.1021/bi9011379 · Cited by 114
Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease
Biskup, S., & West, A. B. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.09.015 · Cited by 108
Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2
Covy, J. P., & Giasson, B. I. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.11.048 · Cited by 94
The Protein Kinase A Inhibitor H89 Acts on Cell Morphology by Inhibiting Rho Kinase
Leemhuis, J., Boutillier, S., Schmidt, G., & Meyer, D. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.1000 · Cited by 79
Hu, Y., Green, N., Gavrin, L. K., Janz, K., Kaila, N., Li, H., Thomason, J. R., Cuozzo, J. W., Hall, J. P., Hsu, S., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.08.102 · Cited by 66
Tokumitsu, H., Inuzuka, H., Ishikawa, Y., & Kobayashi, R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213183200 · Cited by 51
Cited by
Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases
Steger, M., Tonelli, F., Ito, G., Davies, P., Trost, M., Vetter, M., Wachter, S., Lorentzen, E., Duddy, G., Wilson, S., et al. (2016) · eLife · doi:10.7554/elife.12813 · Cited by 1,042
Self-citationLRRK2 activation in idiopathic Parkinson’s disease
Di Maio, R., Hoffman, E. K., Rocha, E. M., Keeney, M. T., Sanders, L. H., De Miranda, B. R., Zharikov, A., Van Laar, A., Stepan, A. F., Lanz, T. A., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar5429 · Cited by 564
Self-citationThe role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease
Cookson, M. R. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2935 · Cited by 539
LRRK2 Inhibition Attenuates Microglial Inflammatory Responses
Moehle, M. S., Webber, P. J., Tse, T., Sukar, N., Standaert, D. G., DeSilva, T. M., Cowell, R. M., & West, A. B. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5601-11.2012 · Cited by 463
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2
Deng, X., Dzamko, N., Prescott, A., Davies, P., Liu, Q., Yang, Q., Lee, J.-D., Patricelli, M. P., Nomanbhoy, T. K., Alessi, D. R., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.538 · Cited by 417
Self-citation
Metadata
- Authors
- Dzamko, N., Deak, M., Hentati, F., Reith, A. D., Prescott, A. R., Alessi, D. R., & Nichols, R. J.
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 2010-08-27
- Volume
- 430
- Issue
- 3
- Pages
- 405-413
- ISSN
- 0264-6021 (ISSN-L)
- 1470-8728
- OpenAlex
- W2004536040
- Cited by
- 372
- References
- 55
- FWCI
- 14.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.